Skip to content
PodSubs
ShowsPeopleGuestsJobsNewsEvents
More
BlogPodCred
Menu
ShowsPeopleGuestsJobsNewsEventsBlogPodCredNetworksSign in
Join nowSign in
  • Shows
  • People
  • Jobs
  • News
  • More
    • Guests
    • Events
    • Blog
    • PodCred
    • Networks
    Join nowSign in

MAP - Market Access Podcast

MAP - Market Access Podcast artwork

What Will It Take to Keep Biotech Growing in Europe, Rainer Westermann?

Oct 1, 202642 minAudio
ShareXLinkedInFacebookWhatsAppEmail

In this episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with Rainer Westermann, Chairman of the Life Sciences Acceleration Alliance (LSAA), to ask whether Europe can remain a globally competitive home for life sciences innovation - and what has to change for new therapies to reach patients. Bringing an investor's lens, Rainer explains why so many promising European companies scale in the US instead: the "valley of death" between great science and a viable business, the shortage of productive growth capital, the absence of a deep, liquid capital market, and the drag of long timelines, fragmented member-state systems, and cost-containment-first thinking. They also unpack the ripple effects of the US Most Favored Nation policy, the patent cliff, and why patients - who are also voters - belong at the center of the debate. Stay connected by subscribing on your favorite podcast platform or listening directly on our website: MAP Podcasts - and if you enjoyed the episode, don't forget to rate it and the podcast! MAP is the first and only bi-weekly market access podcast provided by MArS - and the global #1 podcast in the field of health economics. For more information about MArS Market Access and Pricing Strategy, visit: https://marketaccess4-0.com/ #MarketAccess #LifeSciences #Biotech #VentureCapital #PharmaInnovation #HealthcareInvestment #EuropeanUnion #MFN #MarketAccessStrategy #marketaccesspodcast

Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.

Hosts and Guests

Nobody is credited on this episode yet.

Credit the people on this episode

Be the first to rate this episode

More episodes

All episodes
  1. How Will the EU JCA Reshape National HTA Across Europe, Dr. Oriol Solà-Morales?

    Nov 15, 202640 minAudio

    Is the EU Joint Clinical Assessment just another administrative layer, or the start of a truly European HTA? In this MAP episode, Dr. Stefan Walzer talks with Dr. Oriol Solà-Morales, physician, health economist, founder...

    Credit the people on this episode

  2. How Can HEOR Teams Build Trust in AI-Generated Models, Haidong Feng?

    Nov 1, 202639 minAudio

    AI is reshaping health economics and outcomes research (HEOR) - but where does it truly belong? In this MAP episode, Dr. Stefan Walzer talks with Haidong Feng, Associate Principal Scientist at Merck, about “human in the...

    Credit the people on this episode

  3. Can US GLOBE and GUARD Models Really Lower Drug Prices, Brittany La Couture?

    Oct 15, 202645 minAudio

    When the US benchmarks drug prices against other countries, the whole world feels it. In this episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with Brittany La Couture of Applied Policy, a health...

    Credit the people on this episode

  4. How Do You Build a High-Performing Team in Pharma, Dr. Maurice Kléber?

    Sep 15, 202639 minAudio

    In this episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Maurice Kléber to explore what building a winning team really takes - drawing on 18 years of leadership and a shared love of ice...

    Credit the people on this episode

  5. Where Does AI Really Add Value in Market Access, Dr. Seye Abogunrin?

    Sep 1, 202638 minAudio

    Everyone wants AI to click the button for them - the real question is whether you still need to click it at all. In this episode of MAP - the Market Access Podcast, Dr. Stefan Walzer sits down with Dr. Seye Abogunrin, a...

    Credit the people on this episode